Longeveron (LGVN) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | TPST |
|---|---|---|
| Share price | $1.66 | $0.287 |
| Market cap | $5.60M | $5.74M |
| 1-day change | -8.79% | -6.18% |
| YTD return | — | -90.00% |
| 1-year return | — | -91.80% |
| 5-year return | — | -99.77% |
| EPS (TTM) | $-7.95 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.20M | — |
| Revenue growth (YoY) | -49.87% | — |
| Net income (latest FY) | $-22.70M | $-26.26M |
| Gross margin | 66.97% | — |
| Operating margin | -1942.20% | — |
| Net margin | -1893.58% | — |
| 52-week high | $12.30 | $4.22 |
| 52-week low | $1.31 | $0.28 |
| Distance from 52-week high | -86.50% | -93.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +3589.76% | +2339.02% |
| Average volume | 115.35K | 2.56M |
| Shares outstanding | 3.23M | 20.00M |
| Employees | 38 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
LGVN vs TPST FAQ
Which is bigger, Longeveron or Tempest Therapeutics?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.60M for Longeveron (LGVN).
Are Longeveron and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.